Phosphate therapy in diabetic ketoacidosis

H. K. Wilson, S. P. Keuer, Alfred Lea, A. E. Boyd, G. Eknoyan

Research output: Contribution to journalArticle

Abstract

To determine the efficacy of phosphate replacement in the therapy for diabetic ketoacidosis (DKA), 44 patients were randomly assigned to three treatment groups: those who received no phosphate replacement, those who received 15 mmole of sodium phosphate at the fourth hour, or those who received 15 mmole of sodium phosphate at 2, 6, and 10 hours. All patients were treated with intravenous insulin injection (0.1 units/kg/hr), fluids, and potassium. Four hours after a 15-mmole sodium phosphate infusion, the serum phosphate level was 2.8 ± 0.8 mg/dL vs 2.1 ± 0.8 mg/dL in the control patients; however, this dose was insufficient to maintain the serum phosphate level at 16 and 24 hours. Forty-five millimoles of phosphate prevented severe hypophosphatemia in all but one patient and produced substantially higher phosphate levels at 8, 16, and 24 hours. Phosphate therapy did not affect the duration of DKA, dose of insulin required to correct the acidosis, abnormal muscle enzyme levels, glucose disappearance, or morbidity and mortality. Although theoretically appealing, phosphate therapy is not an essential part of the therapy for DKA in most patients.

Original languageEnglish (US)
Pages (from-to)517-520
Number of pages4
JournalArchives of Internal Medicine
Volume142
Issue number3
DOIs
StatePublished - 1982
Externally publishedYes

Fingerprint

Diabetic Ketoacidosis
Phosphates
Therapeutics
Insulin
Hypophosphatemia
Acidosis
Serum
Intravenous Injections
Potassium
Morbidity
Glucose
Muscles
Mortality
Enzymes

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Wilson, H. K., Keuer, S. P., Lea, A., Boyd, A. E., & Eknoyan, G. (1982). Phosphate therapy in diabetic ketoacidosis. Archives of Internal Medicine, 142(3), 517-520. https://doi.org/10.1001/archinte.142.3.517

Phosphate therapy in diabetic ketoacidosis. / Wilson, H. K.; Keuer, S. P.; Lea, Alfred; Boyd, A. E.; Eknoyan, G.

In: Archives of Internal Medicine, Vol. 142, No. 3, 1982, p. 517-520.

Research output: Contribution to journalArticle

Wilson, HK, Keuer, SP, Lea, A, Boyd, AE & Eknoyan, G 1982, 'Phosphate therapy in diabetic ketoacidosis', Archives of Internal Medicine, vol. 142, no. 3, pp. 517-520. https://doi.org/10.1001/archinte.142.3.517
Wilson, H. K. ; Keuer, S. P. ; Lea, Alfred ; Boyd, A. E. ; Eknoyan, G. / Phosphate therapy in diabetic ketoacidosis. In: Archives of Internal Medicine. 1982 ; Vol. 142, No. 3. pp. 517-520.
@article{e8d0a40def3e44f383839e70697ac441,
title = "Phosphate therapy in diabetic ketoacidosis",
abstract = "To determine the efficacy of phosphate replacement in the therapy for diabetic ketoacidosis (DKA), 44 patients were randomly assigned to three treatment groups: those who received no phosphate replacement, those who received 15 mmole of sodium phosphate at the fourth hour, or those who received 15 mmole of sodium phosphate at 2, 6, and 10 hours. All patients were treated with intravenous insulin injection (0.1 units/kg/hr), fluids, and potassium. Four hours after a 15-mmole sodium phosphate infusion, the serum phosphate level was 2.8 ± 0.8 mg/dL vs 2.1 ± 0.8 mg/dL in the control patients; however, this dose was insufficient to maintain the serum phosphate level at 16 and 24 hours. Forty-five millimoles of phosphate prevented severe hypophosphatemia in all but one patient and produced substantially higher phosphate levels at 8, 16, and 24 hours. Phosphate therapy did not affect the duration of DKA, dose of insulin required to correct the acidosis, abnormal muscle enzyme levels, glucose disappearance, or morbidity and mortality. Although theoretically appealing, phosphate therapy is not an essential part of the therapy for DKA in most patients.",
author = "Wilson, {H. K.} and Keuer, {S. P.} and Alfred Lea and Boyd, {A. E.} and G. Eknoyan",
year = "1982",
doi = "10.1001/archinte.142.3.517",
language = "English (US)",
volume = "142",
pages = "517--520",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "3",

}

TY - JOUR

T1 - Phosphate therapy in diabetic ketoacidosis

AU - Wilson, H. K.

AU - Keuer, S. P.

AU - Lea, Alfred

AU - Boyd, A. E.

AU - Eknoyan, G.

PY - 1982

Y1 - 1982

N2 - To determine the efficacy of phosphate replacement in the therapy for diabetic ketoacidosis (DKA), 44 patients were randomly assigned to three treatment groups: those who received no phosphate replacement, those who received 15 mmole of sodium phosphate at the fourth hour, or those who received 15 mmole of sodium phosphate at 2, 6, and 10 hours. All patients were treated with intravenous insulin injection (0.1 units/kg/hr), fluids, and potassium. Four hours after a 15-mmole sodium phosphate infusion, the serum phosphate level was 2.8 ± 0.8 mg/dL vs 2.1 ± 0.8 mg/dL in the control patients; however, this dose was insufficient to maintain the serum phosphate level at 16 and 24 hours. Forty-five millimoles of phosphate prevented severe hypophosphatemia in all but one patient and produced substantially higher phosphate levels at 8, 16, and 24 hours. Phosphate therapy did not affect the duration of DKA, dose of insulin required to correct the acidosis, abnormal muscle enzyme levels, glucose disappearance, or morbidity and mortality. Although theoretically appealing, phosphate therapy is not an essential part of the therapy for DKA in most patients.

AB - To determine the efficacy of phosphate replacement in the therapy for diabetic ketoacidosis (DKA), 44 patients were randomly assigned to three treatment groups: those who received no phosphate replacement, those who received 15 mmole of sodium phosphate at the fourth hour, or those who received 15 mmole of sodium phosphate at 2, 6, and 10 hours. All patients were treated with intravenous insulin injection (0.1 units/kg/hr), fluids, and potassium. Four hours after a 15-mmole sodium phosphate infusion, the serum phosphate level was 2.8 ± 0.8 mg/dL vs 2.1 ± 0.8 mg/dL in the control patients; however, this dose was insufficient to maintain the serum phosphate level at 16 and 24 hours. Forty-five millimoles of phosphate prevented severe hypophosphatemia in all but one patient and produced substantially higher phosphate levels at 8, 16, and 24 hours. Phosphate therapy did not affect the duration of DKA, dose of insulin required to correct the acidosis, abnormal muscle enzyme levels, glucose disappearance, or morbidity and mortality. Although theoretically appealing, phosphate therapy is not an essential part of the therapy for DKA in most patients.

UR - http://www.scopus.com/inward/record.url?scp=0020062376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020062376&partnerID=8YFLogxK

U2 - 10.1001/archinte.142.3.517

DO - 10.1001/archinte.142.3.517

M3 - Article

C2 - 6802095

VL - 142

SP - 517

EP - 520

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 3

ER -